TNF Pharmaceuticals, Inc.

NasdaqCM:TNFA Stock Report

Market Cap: US$3.7m

TNF Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure1.5yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

Sep 01
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate

May 19
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate

MyMD Pharma receives grant from European patent office for Supera-CBD compound

Aug 30

Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3

Jul 08

Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky

Apr 12
Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky

MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans

Aug 29
MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans

CEO

TNF Pharmaceuticals has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Ian Rhodes
Interim Chief Financial Officer3.8yrsUS$162.00kno data
Mitchell Glass
Presidentless than a yearno datano data
Robert Schatz
Investor Relations Officerno datano datano data
Jenna Brager
Executive Vice President of Drug Development1.5yrsno datano data

1.5yrs

Average Tenure

Experienced Management: TNFA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mitchell Glass
Presidentless than a yearno datano data
Joshua Silverman
Independent Chairman of the Board6.3yrsUS$216.00k0.11%
$ 4.0k
Stephen Friscia
Independent Directorless than a yearno datano data
Christopher Schreiber
Director7.3yrsUS$310.89k0.11%
$ 4.0k
Craig Eagle
Independent Director3.7yrsUS$96.00k0%
$ 0
Billy White
Independent Director7.3yrsUS$96.00k0.089%
$ 3.3k
Jeremy Walston
Member of Scientific Advisory Boardno datano datano data
Jude Uzonwanne
Independent Director3.7yrsUS$96.00k0%
$ 0

3.7yrs

Average Tenure

58yo

Average Age

Experienced Board: TNFA's board of directors are considered experienced (3.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TNF Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution